Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Public ClinicalTrials.gov record NCT05462717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Study identification
- NCT ID
- NCT05462717
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2022
- Primary completion
- Mar 30, 2027
- Completion
- Sep 29, 2027
- Last update posted
- May 14, 2026
2022 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| UC Irvine Cancer Center | Orange | California | 92868 | — |
| UC Davis Cancer Center | Sacramento | California | 95817 | — |
| UCSF | San Francisco | California | 94158 | — |
| University of Miami School of Medicine Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| American Oncology Partners of Maryland | Bethesda | Maryland | 20817 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
| MSK Cancer Center | New York | New York | 10021 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Next Oncology | San Antonio | Texas | 78229 | — |
| START | San Antonio | Texas | 78229 | — |
| Next Oncology Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
Recently updated Advanced Solid Tumor trials
Other public records listing Advanced Solid Tumor. Sorted by last update posted; newest first. Not a recommendation.
- NCT07751042: Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab Recruiting
- NCT07749586: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting
- NCT07602842: A Study of IDP-001 in Advanced or Metastatic Solid Tumors Recruiting
- NCT06244485: A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Active, not recruiting
- NCT05098132: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers Recruiting
- NCT06352359: Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05462717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05462717 live on ClinicalTrials.gov.